Show simple item record

dc.contributor.authorYildiz, Aladdin
dc.contributor.authorTurunc, Volkan
dc.contributor.authorAri, Elif
dc.contributor.authorGuven, Bahtisen
dc.contributor.authorTabendeh, Babek
dc.date.accessioned2021-03-03T08:21:45Z
dc.date.available2021-03-03T08:21:45Z
dc.date.issued2019
dc.identifier.citationTurunc V., Ari E., Guven B., Tabendeh B., Yildiz A., "Once- vs Twice-Daily Tacrolimus: Survival Rates and Side Effects: Single-Center Experience", TRANSPLANTATION PROCEEDINGS, cilt.51, sa.7, ss.2308-2311, 2019
dc.identifier.issn0041-1345
dc.identifier.otherav_1718de92-ebc9-4d72-87b5-0b7bd530ee5a
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/20868
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2019.01.149
dc.description.abstractBackground. This study aimed to determine whether de novo, prolonged-release tacrolimus- (PR-tacro) based immunosuppressive regimen affected graft and patient survival when compared to an immediate-release, twice-daily, tacrolimus- (IR-tacro) based regimen in kidney transplant recipients. We also aimed to determine the difference between the frequency of side effects, including diabetes control, in study groups.
dc.language.isoeng
dc.subjectKlinik Tıp (MED)
dc.subjectTRANSPLANTASYON
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectCerrahi Tıp Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectCERRAHİ
dc.subjectKlinik Tıp
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectİmmünoloji
dc.titleOnce- vs Twice-Daily Tacrolimus: Survival Rates and Side Effects: Single-Center Experience
dc.typeMakale
dc.relation.journalTRANSPLANTATION PROCEEDINGS
dc.contributor.departmentBahçeşehir Üniversitesi , ,
dc.identifier.volume51
dc.identifier.issue7
dc.identifier.startpage2308
dc.identifier.endpage2311
dc.contributor.firstauthorID267356


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record